## PTO/SB/26 (08-03) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING

Docket Number (Optional)

REJECTION OVER A PRIOR PATENT	226272003802
In re Application of: Andrew L. FELDHAUS	
Application No.: 09/909,363	
Filed: July 19, 2001	
For: TRANSCRIPTIONALLY-ACTIVATED AAV INVERTED TERMINAL REPEATS (ITRS) FOR USE WITH RECOMBINANT AAV VECTORS	
The owner, Targeted Genetics Corporation , of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. 6,346,415 . The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.	
In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.	
Check either box 1 or 2 below, if appropriate.	
1. X For submissions on behalf of an organization (e.g., corporation, partnership, university the undersigned is empowered to act on behalf of the organization.	ity, government agency, etc.),
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.	
2. The undersigned is an attorney or agent of record.	
Forme Jal Signature	8 17 04 Date
Burne J. Cutco	
206-623-7612 Telephone Nu	mber
Terminal disclaimer fee under 37 CFR 1.20(d) is included.	
*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP § 324.	
EMA1 00000007 031952 09909363 55.00 DA	

09/20/2004 KBET 01 FC:2814



PTO/SB/96 (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)	
Applicant/Patent Owner: Andrew L. FELDHAUS	
Application No./Patent No.: 09/909,363 Filed/Issue Date: July 19, 2001	
TRANSCRIPTIONALLY-ACTIVATED AAV INVERTED TERMINAL REPEATS (ITRS) FOR USE WITH RECOMBINANT AAV VECTORS	
Targeted Genetics Corporation , a corporation (Name of Assignee) , a corporation (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)	
states that it is:	
1. X the assignee of the entire right, title, and interest; or	
2. an assignee of less than the entire right, title and interest.  The extent (by percentage) of its ownership interest is %  in the patent application/patent identified above by virtue of either:	
A. [x] An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 010645, Frame 0264, or for which a copy thereof is attached.	
<ul> <li>B. [ ] A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:</li> </ul>	
1. From: To:	
The document was recorded in the United States Patent and Trademark Office at	
Reel , Frame , or for which a copy thereof is attached.	
2. From: To:	
The document was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.	
3. From: To:	
The document was recorded in the United States Patent and Trademark Office at	
Reel , Frame , or for which a copy thereof is attached.	
[ ] Additional documents in the chain of title are listed on a supplemental sheet.	
[ ] Copies of assignments or other documents in the chain of title are attached. [NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]	
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.	
8 17 104 Targeted Genetics Corporation	
Date Typed or printed name	
106-62-7612 (Varie) Cl	
Telephone Number  Signature	
Title	